Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo, Kaketsuken Terminate Vaccine Sales Partnership
May 9, 2018
- US FDA Approves Myrbetriq/Vesicare Combination Therapy for OAB: Astellas
May 9, 2018
- Kissei Mulls Over Urief AG Launch
May 9, 2018
- MHLW Official Hails Takeda’s Shire Takeover
May 9, 2018
- Takeda Cuts Deal to Acquire Shire in Japan’s Biggest Buyout
May 8, 2018
- Spiolto Improves Lung Function in Japanese COPD Patients against Spiriva in Trial: BI
May 8, 2018
- XLH Drug Crysvita Now Available in US: Kyowa Kirin/Ultragenyx
May 8, 2018
- FDA OKs Label Update for Takeda/Lundbeck’s Trintellix
May 8, 2018
- Over 60% of Drug Makers Cut New Grad Hires in FY2018, Otsuka Tops List Again: Tally
May 8, 2018
- Kyowa Kirin to Focus on New Drugs in Europe, US to Achieve Midterm Targets: New President
May 7, 2018
- Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
- Daiichi Sankyo to Streamline Vaccine Business in April 2019, Setting Up New Manufacturing Company
May 7, 2018
- Japan to Join Jardiance Study for CKD under Collaboration between Boehringer, Lilly, and Oxford
May 2, 2018
- Takeda’s Takeover Bid for Shire “Thought-Provoking”: Daiichi Sankyo CEO
May 1, 2018
- Despite Upbeat AGs, Daiichi Sankyo to Closely Watch Pricing Environment: CEO
May 1, 2018
- Daiichi Sankyo to Announce “Important Measures” to Shore Up Biz by 2nd Qtr Earnings
May 1, 2018
- Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
- Keytruda-Chemo Combo Filed for NSCLC without PD-L1 Cutoff
May 1, 2018
- Sumitomo Dainippon Slashes FY2017 Profit Outlook
April 27, 2018
- Boehringer Ingelheim Japan Sees 10% Dip in Pharma Sales as Micardis LOE Weighs
April 27, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…